The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 708K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

13 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
ExploringEBI
University of California San Francisco
Tuning the Biological Activity of RGD Peptides with Halotryptophans†.EBI
Bielefeld University
Discovery of the first potent and selective αEBI
University of Strathclyde
Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness.EBI
University of California San Francisco
Novel cilengitide-based cyclic RGD peptides as αvβEBI
Division of Organic Chemistry Csir-National Chemical Laboratory (Ncl)
Selective Targeting of Integrin αvβ8 by a Highly Active Cyclic Peptide.EBI
Technische Universit£T M£Nchen
Profile of a Highly Selective Quaternized Pyrrolidine Betaine αEBI
Glaxosmithkline Medicines Research Centre
Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.EBI
University of Bradford
Structure Activity Relationships of αv Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents.EBI
University of Nottingham
Discovery of ( S)-3-(3-(3,5-Dimethyl-1 H-pyrazol-1-yl)phenyl)-4-(( R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic αEBI
University of Strathclyde
Matrix metalloproteinase (MMP) inhibitors and methods of use thereofBDB
Foresee Pharmaceuticals
TrkA kinase inhibitors, compositions and methods thereofBDB
Merck Sharp & Dohme
Synthesis of 5,6-dihydro-4H-benzo[d]isoxazol-7-one and 5,6-dihydro-4H-isoxazolo[5,4-c]pyridin-7-one derivatives as potential Hsp90 inhibitors.BDB
University of Milano